메뉴 건너뛰기




Volumn 18, Issue 2, 2014, Pages 278-281

Statins in chronic kidney disease: What do meta-analyses tell us?

Author keywords

Chronic kidney disease; Dyslipidemia; Meta analysis; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 84900302195     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0889-2     Document Type: Review
Times cited : (4)

References (14)
  • 1
    • 4644221457 scopus 로고    scopus 로고
    • Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    • Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
    • (2004) N Engl J Med , vol.351 , pp. 1296-1305
    • Go, A.S.1    Chertow, G.M.2    Fan, D.3    McCulloch, C.E.4    Hsu, C.Y.5
  • 2
    • 0031733360 scopus 로고    scopus 로고
    • Hyperlipidemia in patients with chronic renal disease
    • Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S142-56. (Pubitemid 28527270)
    • (1998) American Journal of Kidney Diseases , vol.32 , Issue.5 SUPPL. 3
    • Kasiske, B.L.1
  • 3
    • 84865602423 scopus 로고    scopus 로고
    • Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study
    • Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807-14.
    • (2012) Lancet , vol.380 , pp. 807-814
    • Tonelli, M.1    Muntner, P.2    Lloyd, A.3    Manns, B.J.4    Klarenbach, S.5    Pannu, N.6
  • 4
    • 83055172414 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease
    • Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
    • Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(Suppl 3):S1-77.
    • (2003) Am J Kidney Dis , vol.41 , Issue.SUPPL. 3
  • 6
    • 33749035484 scopus 로고    scopus 로고
    • Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control
    • DOI 10.1001/archinte.166.17.1884
    • Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884-91. (Pubitemid 44455172)
    • (2006) Archives of Internal Medicine , vol.166 , Issue.17 , pp. 1884-1891
    • Parikh, N.I.1    Hwang, S.-J.2    Larson, M.G.3    Meigs, J.B.4    Levy, D.5    Fox, C.S.6
  • 7
    • 0035127168 scopus 로고    scopus 로고
    • Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency
    • Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-9. (Pubitemid 32195286)
    • (2001) American Journal of Kidney Diseases , vol.37 , Issue.3 , pp. 484-489
    • Tonelli, M.1    Bohm, C.2    Pandeya, S.3    Gill, J.4    Levin, A.5    Kiberd, B.A.6
  • 8
    • 84865658424 scopus 로고    scopus 로고
    • Lipid-lowering therapy in persons with chronic kidney disease: A systematic review and meta-analysis
    • Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:251-62.
    • (2012) Ann Intern Med , vol.157 , pp. 251-262
    • Upadhyay, A.1    Earley, A.2    Lamont, J.L.3    Haynes, S.4    Wanner, C.5    Balk, E.M.6
  • 9
    • 84865628946 scopus 로고    scopus 로고
    • Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis
    • Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-75.
    • (2012) Ann Intern Med , vol.157 , pp. 263-275
    • Palmer, S.C.1    Craig, J.C.2    Navaneethan, S.D.3    Tonelli, M.4    Pellegrini, F.5    Strippoli, G.F.6
  • 10
    • 41449093519 scopus 로고    scopus 로고
    • Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials
    • DOI 10.1136/bmj.39472.580984.AE
    • Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645-51. (Pubitemid 351481234)
    • (2008) BMJ , vol.336 , Issue.7645 , pp. 645-651
    • Strippoli, G.F.M.1    Navaneethan, S.D.2    Johnson, D.W.3    Perkovic, V.4    Pellegrini, F.5    Nicolucci, A.6    Craig, J.C.7
  • 13
    • 84874026581 scopus 로고    scopus 로고
    • The management of dyslipidemia in CKD: New analyses of an expanding dataset
    • Kasiske BL, Wheeler DC. The management of dyslipidemia in CKD: new analyses of an expanding dataset. Am J Kidney Dis. 2013;61:371-4.
    • (2013) Am J Kidney Dis , vol.61 , pp. 371-374
    • Kasiske, B.L.1    Wheeler, D.C.2
  • 14
    • 84883464989 scopus 로고    scopus 로고
    • LDL cholesterol in CKD - To treat or not to treat?
    • Massy ZA, de Zeeuw D. LDL cholesterol in CKD - to treat or not to treat? Kidney Int. 2013;84:451-6.
    • (2013) Kidney Int , vol.84 , pp. 451-456
    • Massy, Z.A.1    De Zeeuw, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.